Jon E. Angell

Array ( [id] => 16206904 [patent_doc_number] => 20200239894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTISENSE DRUGS AGAINST CANINE ICAM-1 FOR USE IN THE TREATMENT OF INFLAMMATION OF THE BUCCAL CAVITY [patent_app_type] => utility [patent_app_number] => 16/634019 [patent_app_country] => US [patent_app_date] => 2018-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13549093 [patent_doc_number] => 20180326094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING KELOID OR HYPERTROPHIC SCARS [patent_app_type] => utility [patent_app_number] => 16/028283 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9172 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16028283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13827127 [patent_doc_number] => 20190017048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF USHER SYNDROME TYPE 2 [patent_app_type] => utility [patent_app_number] => 16/027451 [patent_app_country] => US [patent_app_date] => 2018-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16027451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460610 [patent_doc_number] => 20220073915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => ARTIFICIAL NUCLEIC ACIDS FOR RNA EDITING [patent_app_type] => utility [patent_app_number] => 17/256092 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21854 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17256092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533534 [patent_doc_number] => 10876119 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Reduced size self-delivering RNAI compounds [patent_app_type] => utility [patent_app_number] => 16/022652 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 107 [patent_no_of_words] => 59334 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16022652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808264 [patent_doc_number] => 20210130817 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => Gene Editing System and Gene Editing Method [patent_app_type] => utility [patent_app_number] => 16/630795 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630795 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15828513 [patent_doc_number] => 20200129538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-30 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH GAIN-OF-FUNCTION MUTATIONS IN KCNT1 [patent_app_type] => utility [patent_app_number] => 16/622249 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13871437 [patent_doc_number] => 20190032059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Gene Vector [patent_app_type] => utility [patent_app_number] => 16/004394 [patent_app_country] => US [patent_app_date] => 2018-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22760 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16004394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866915 [patent_doc_number] => 20200140861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => LONG NON-CODING RNA IN CANCER [patent_app_type] => utility [patent_app_number] => 16/620700 [patent_app_country] => US [patent_app_date] => 2018-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10468 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16620700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14231123 [patent_doc_number] => 20190127734 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => MIR-29 MIMICS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/002845 [patent_app_country] => US [patent_app_date] => 2018-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13533685 [patent_doc_number] => 20180318385 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 15/996140 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68868 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15996140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13760959 [patent_doc_number] => 10172808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Combinations of mRNAs encoding immune modulating polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 15/995889 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 76 [patent_figures_cnt] => 146 [patent_no_of_words] => 148623 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13729813 [patent_doc_number] => 20180369374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/996146 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 276688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15996146 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413775 [patent_doc_number] => 20180258430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => Compositions and Methods for Inhibiting Gene Expression of Alpha-1 AntiTrypsin [patent_app_type] => utility [patent_app_number] => 15/990330 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15681837 [patent_doc_number] => 20200095582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => BCL11A GUIDE DELIVERY [patent_app_type] => utility [patent_app_number] => 16/616224 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711195 [patent_doc_number] => 20200102363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/613732 [patent_app_country] => US [patent_app_date] => 2018-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -100 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17220707 [patent_doc_number] => 11173190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-16 [patent_title] => Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR [patent_app_type] => utility [patent_app_number] => 15/981757 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 26128 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17163180 [patent_doc_number] => 11149269 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability [patent_app_type] => utility [patent_app_number] => 16/613322 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 20 [patent_no_of_words] => 18954 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 159 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18764239 [patent_doc_number] => 11814626 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-14 [patent_title] => Compositions and methods for loading extracellular vesicles with chemical and biological agents/molecules [patent_app_type] => utility [patent_app_number] => 16/612734 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 23 [patent_no_of_words] => 15602 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17178581 [patent_doc_number] => 11155816 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-26 [patent_title] => Oligonucleotide conjugates [patent_app_type] => utility [patent_app_number] => 15/974086 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 27 [patent_no_of_words] => 49180 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974086 [rel_patent_id] =>[rel_patent_doc_number] =>)